

Mr I. Rawe  
BioElectronics Corporation  
4539 Metropolitan Ct.  
Frederick, MD. 21704  
USA

**Drug Tariff Team**  
NHS Prescription Services  
3<sup>rd</sup> Floor Annex  
Bridge House  
152 Pilgrim Street  
Newcastle upon Tyne  
NE1 6SN

Tel : 0191 229 3652

Email: [nhsbsa.pixie@nhs.net](mailto:nhsbsa.pixie@nhs.net)

Website: [www.nhsbsa.nhs.uk/prescriptions](http://www.nhsbsa.nhs.uk/prescriptions)

Ref: ZCE 1/376/1

Date : 19 December 2017

Dear Mr Rawe

## ActiPatch

I am pleased to confirm that the application for the above product to be included within Drug Tariff Part IX has been successful.

We intend to list this product in the April 2018 edition of the Drug Tariff unless you inform us that you require listing to be delayed.

As a manufacturer of a new addition to Drug Tariff Part IX, we need to advise you of the price rise procedure for products listed in Part IX. The procedure (as agreed between the Department of Health (DH) and the Drug Tariff Part IX Forum) is as follows.

*“Manufacturers may seek price rises for a product once a year or any longer period. The maximum rise will be the forecast of the gross domestic product (GDP) deflator minus 0.75”.* Further details of this agreement are available on our website

<https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/drug-tariff/prescriptions-drug-tariff-part-ix> under the sub-heading Part IX price increase mechanism.

As communicated through the Part IX Drug Tariff Forum, there is an initiative to provide a wider and up to date coverage of GTIN (formerly European Article Number) codes on the NHS dm+d. Please provide the GTINs for your recently approved product, if they are available, on the attached spreadsheet. Inclusion of GTINs in dm+d will help support future prescribing and pharmacy working practices, patient safety, and NHS business processes. However, we appreciate that it may not be possible or appropriate to provide GTINs for all products and their supply is not obligatory. Please note that we can only receive GTINs provided to us electronically on the spreadsheet provided.

Please confirm in writing by 16 February 2018 the following; that supplies will be readily available from 1 April 2018 and that you have the distribution rights for your product for England and Wales. Also, please check the proposed entry carefully - this is the exact final format of the entry in the published Drug Tariff. If this information is received after 16 February 2018 we regret that entry will be delayed until May 2018.

If you have any queries regarding your application or the application process please email [nhsbsa.pixie@nhs.net](mailto:nhsbsa.pixie@nhs.net).

Yours sincerely

A handwritten signature in black ink, appearing to read 'Thawheeda Khan', written in a cursive style.

Thawheeda Khan  
Drug Tariff Data Analyst